Literature DB >> 22818564

A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2.

Raul D Santos1, David D Waters, Lisa Tarasenko, Michael Messig, J Wouter Jukema, Cheng-Wen Chiang, Jean Ferrieres, Joanne M Foody.   

Abstract

OBJECTIVE: This study evaluated the success in attaining non-HDL-cholesterol (non-HDL-C) goals in the multinational L-TAP 2 study.
METHODS: 9955 patients ≥20 years of age with dyslipidemia on stable lipid-lowering therapy were enrolled from nine countries.
RESULTS: Success rates for non-HDL-C goals were 86% in low, 70% in moderate, and 52% in high-risk patients (63% overall). In patients with triglycerides of >200 mg/dL success rates for non-HDL-C goals were 35% vs. 69% in those with ≤200 mg/dL (p < 0.0001). Among patients attaining their LDL-C goal, 18% did not attain their non-HDL-C goal. In those with coronary disease and at least two risk factors, only 34% and 30% attained respectively their non-HDL-C and LDL-C goals. Rates of failure in attaining both LDL-C and non-HDL-C goals were highest in Latin America.
CONCLUSIONS: Non-HDL-C goal attainment lagged behind LDL-C goal attainment; this gap was greatest in higher-risk patients.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22818564     DOI: 10.1016/j.atherosclerosis.2012.06.052

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Gualtiero Ricciardi; Simona Giampaoli; Aldo Pietro Maggioni; Maurizio Averna; Maria Stella Graziani; Ferruccio Ceriotti; Alessandro Mugelli; Francesco Rossi; Gerardo Medea; Damiano Parretti; Maurizio Giuseppe Abrignani; Marcello Arca; Pasquale Perrone Filardi; Francesco Perticone; Alberico Catapano; Raffaele Griffo; Federico Nardi; Carmine Riccio; Andrea Di Lenarda; Marino Scherillo; Nicoletta Musacchio; Antonio Vittorio Panno; Giovanni Battista Zito; Mauro Campanini; Leonardo Bolognese; Pompilio Massimo Faggiano; Giuseppe Musumeci; Enrico Pusineri; Marcello Ciaccio; Enzo Bonora; Giorgio Cantelli Forti; Maria Pia Ruggieri; Claudio Cricelli; Francesco Romeo; Roberto Ferrari; Attilio Maseri
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

2.  Achievement of LDL Cholesterol Goal and Adherence to Statin by Diabetes Patients in Kelantan.

Authors:  Zainab Mat Yudin; Lili Husniati Yaacob; Norul Badriah Hassan; Saiful Bahari Ismail; Nani Draman; Siti Suhaila Mohd Yusoff
Journal:  Malays J Med Sci       Date:  2017-06-30

Review 3.  The need for combination drug therapies in patients with complex dyslipidemia.

Authors:  James Barnett; Adie Viljoen; Anthony S Wierzbicki
Journal:  Curr Cardiol Rep       Date:  2013-08       Impact factor: 2.931

Review 4.  A Latin American perspective on the new ACC/AHA clinical guidelines for managing atherosclerotic cardiovascular disease.

Authors:  Ada Cuevas; Antonio Arteaga; Attilio Rigotti
Journal:  Curr Atheroscler Rep       Date:  2014-04       Impact factor: 5.113

5.  First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients.

Authors:  Ioanna Xanthopoulou; Periklis Davlouros; Simos Siahos; Angelos Perperis; Evangelia Zaharioglou; Dimitrios Alexopoulos
Journal:  Lipids Health Dis       Date:  2013-11-09       Impact factor: 3.876

6.  Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Authors:  Elizabeth Marrett; Changgeng Zhao; Ning Jackie Zhang; Qiaoyi Zhang; Dena R Ramey; Joanne E Tomassini; Andrew M Tershakovec; David R Neff
Journal:  Vasc Health Risk Manag       Date:  2014-04-25

7.  Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.

Authors:  Ngoc-Anh Le; Joanne E Tomassini; Andrew M Tershakovec; David R Neff; Peter W F Wilson
Journal:  J Am Heart Assoc       Date:  2015-10-20       Impact factor: 5.501

8.  Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population.

Authors:  Sabrina Angelini; Martina Rosticci; Gianmichele Massimo; Muriel Musti; Gloria Ravegnini; Nicola Consolini; Giulia Sammarini; Sergio D'Addato; Elisabetta Rizzoli; Dauren Botbayev; Claudio Borghi; Giorgio Cantelli-Forti; Arrigo F Cicero; Patrizia Hrelia
Journal:  Int J Mol Sci       Date:  2017-12-24       Impact factor: 5.923

9.  SAK-HV Triggered a Short-period Lipid-lowering Biotherapy Based on the Energy Model of Liver Proliferation via a Novel Pathway.

Authors:  Chao Zhang; Zhiguang Huang; Haoran Jing; Wenliang Fu; Min Yuan; Wenrong Xia; Ling Cai; Xiangdong Gan; Yao Chen; Minji Zou; Minhui Long; Jiaxi Wang; Min Wang; Donggang Xu
Journal:  Theranostics       Date:  2017-04-10       Impact factor: 11.556

10.  Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.

Authors:  Abhiram S Rao; Daniel Lindholm; Manuel A Rivas; Joshua W Knowles; Stephen B Montgomery; Erik Ingelsson
Journal:  Circ Genom Precis Med       Date:  2018-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.